Posted by shellson2 on 16th of Jun 2025 at 01:11 pm
PACB--just something to file away--long term play. Obviously a
devasting and unmet disease. Can only hope they or anyone can make
progress with this asap.
Target ALS Chooses PacBio HiFi Sequencing to
Advance ALS Research with Largest Global Genomic Study to Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made
freely available to scientists worldwide
NEW YORK and MENLO PARK, Calif., June 2,
2025 /PRNewswire/ -- Target ALS, a nonprofit breaking
down barriers to amyotrophic lateral sclerosis (ALS) research, has
partnered with PacBio (NASDAQ:
PACB), a
leading provider of high-quality, highly accurate long read
sequencing platforms, to launch the largest global whole genome
sequencing initiative for ALS to date. By applying PacBio's HiFi
sequencing to more than 6,000 genomes from people with ALS and
healthy controls, the project aims to detect structural variants,
repeat expansions, and other hard-to-detect genetic features that
may underlie the disease. As part of the
ALS Global Research Initiative
(AGRI), all data will be openly shared via the
Target ALS Data Engine, removing
barriers to access and enabling researchers around the world to
uncover disease mechanisms and explore new pathways to
treatment.
Posted by shellson2 on 3rd of Jul 2025 at 11:08 am
Volume today already exceeded 10day avg. I’ve been holding for a
long time awaiting a positive chunk of good news to finally get
this puppy going…we’ll see
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
PACB--just something to file away--long
Posted by shellson2 on 16th of Jun 2025 at 01:11 pm
PACB--just something to file away--long term play. Obviously a devasting and unmet disease. Can only hope they or anyone can make progress with this asap.
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide
NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and other hard-to-detect genetic features that may underlie the disease. As part of the ALS Global Research Initiative (AGRI), all data will be openly shared via the Target ALS Data Engine, removing barriers to access and enabling researchers around the world to uncover disease mechanisms and explore new pathways to treatment.
At 3 month high. I
Posted by shellson2 on 2nd of Jul 2025 at 02:05 pm
At 3 month high. I like the volume today
Volume today already exceeded 10day
Posted by shellson2 on 3rd of Jul 2025 at 11:08 am
Volume today already exceeded 10day avg. I’ve been holding for a long time awaiting a positive chunk of good news to finally get this puppy going…we’ll see